Anti-idiotype cancer vaccine - Viventia Biotech

Drug Profile

Anti-idiotype cancer vaccine - Viventia Biotech

Alternative Names: 4B5; Monoclonal antibody 4B5; NOVOVAC-M1

Latest Information Update: 04 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viventia Biotech
  • Class Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 11 Jul 2002 The 4B5 portfolio is available for licensing (http://www.viventia.com)
  • 16 Apr 2002 Preclinical data has been added to the immunogenicity section
  • 18 Jan 2001 A phase I/II trial has been added to the adverse events section and the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top